These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22612698)

  • 1. Antibody-conjugated nanoparticles for therapeutic applications.
    Cardoso MM; Peça IN; Roque AC
    Curr Med Chem; 2012; 19(19):3103-27. PubMed ID: 22612698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies and associates: Partners in targeted drug delivery.
    Kennedy PJ; Oliveira C; Granja PL; Sarmento B
    Pharmacol Ther; 2017 Sep; 177():129-145. PubMed ID: 28315359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment.
    Juan A; Cimas FJ; Bravo I; Pandiella A; Ocaña A; Alonso-Moreno C
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy.
    Hasan M; Alam S; Poddar SK
    Curr Clin Pharmacol; 2018; 13(4):236-251. PubMed ID: 30073930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomaterial-Enabled Cancer Therapy.
    Quader S; Kataoka K
    Mol Ther; 2017 Jul; 25(7):1501-1513. PubMed ID: 28532763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancement of nanoscience in development of conjugated drugs for enhanced disease prevention.
    Taneja P; Sharma S; Sinha VB; Yadav AK
    Life Sci; 2021 Mar; 268():118859. PubMed ID: 33358907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
    Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
    J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of nanoparticle-antibody conjugations: carbodiimide versus click chemistry.
    Thorek DL; Elias DR; Tsourkas A
    Mol Imaging; 2009; 8(4):221-9. PubMed ID: 19728976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy.
    Zhong Y; Meng F; Deng C; Zhong Z
    Biomacromolecules; 2014 Jun; 15(6):1955-69. PubMed ID: 24798476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of harmful tumour-associated proteolysis by nanoparticulate system.
    Kos J; Obermajer N; Doljak B; Kocbek P; Kristl J
    Int J Pharm; 2009 Nov; 381(2):106-12. PubMed ID: 19422896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.
    Raja SM; Desale SS; Mohapatra B; Luan H; Soni K; Zhang J; Storck MA; Feng D; Bielecki TA; Band V; Cohen SM; Bronich TK; Band H
    Oncotarget; 2016 Mar; 7(9):10522-35. PubMed ID: 26859680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-targeted nanoparticles for cancer therapy.
    Fay F; Scott CJ
    Immunotherapy; 2011 Mar; 3(3):381-94. PubMed ID: 21395380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Targeting of Polymeric Nanoparticles Conjugated with Peptides, Saccharides, and Small Molecules for Anticancer Drugs.
    Bayram B; Ozgur A; Tutar L; Tutar Y
    Curr Pharm Des; 2017; 23(35):5349-5357. PubMed ID: 28911307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting.
    Ahmad A; Khan F; Mishra RK; Khan R
    J Med Chem; 2019 Dec; 62(23):10475-10496. PubMed ID: 31339714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells.
    Jiang S; Wang X; Zhang Z; Sun L; Pu Y; Yao H; Li J; Liu Y; Zhang Y; Zhang W
    Int J Nanomedicine; 2016; 11():5505-5518. PubMed ID: 27843311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes.
    Mizrahy S; Hazan-Halevy I; Dammes N; Landesman-Milo D; Peer D
    Mol Ther; 2017 Jul; 25(7):1491-1500. PubMed ID: 28392163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of polymeric nanoparticles in immunotherapy.
    Craparo EF; Bondì ML
    Curr Opin Allergy Clin Immunol; 2012 Dec; 12(6):658-64. PubMed ID: 23095912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical translation of immunoliposomes for cancer therapy: recent perspectives.
    Wang D; Sun Y; Liu Y; Meng F; Lee RJ
    Expert Opin Drug Deliv; 2018 Sep; 15(9):893-903. PubMed ID: 30169978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies.
    Marques AC; Costa PJ; Velho S; Amaral MH
    J Control Release; 2020 Apr; 320():180-200. PubMed ID: 31978444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.